Currently out of the existing stock ratings of Yanan Zhu, 100 are a BUY (75.19%), 33 are a HOLD (24.81%).

Yanan Zhu

Work Performance Price Targets & Ratings Chart

Analyst Yanan Zhu, currently employed at WELLS FARGO, carries an average stock price target met ratio of 44.3% that have a potential upside of 40.97% achieved within 98 days.

Yanan Zhu’s has documented 255 price targets and ratings displayed on 31 stocks. The coverage is on Healthcare, Technology sectors.

Most recent stock forecast was given on MGX, Metagenomi, Common Stock at 12-May-2026.

Wall Street Analyst Yanan Zhu

Analyst best performing recommendations are on RGLS (REGULUS THERAPEUTICS).
The best stock recommendation documented was for QURE (UNIQURE NV) at 3/3/2026. The price target of $15 was fulfilled within 6 days with a profit of $5.97 (66.11%) receiving and performance score of 110.19.

Average potential price target upside

ARGX argenx NV ADR EDIT Editas Medicine RAPT RAPT Therapeutics AVRO AVROBIO BLUE Bluebird bio SGMO Sangamo Therapeutics AGLE Aeglea Bio Therapeutics AGTC Applied Genetic TSHA Taysha Gene Therapies  BEAM Beam Therapeutics  NTLA Intellia Therapeutics AFMD Affimed NV AUTL Autolus Therapeutics Ltd FATE Fate Therapeutics IOVA Iovance Biotherapeutics RNA Avidity Biosciences  GRCL Gracell Biotechnologies TCRT Alaunos Therapeutics IONS Ionis Pharmaceuticals SYRE Spyre Therapeutics ARCT Arcturus Therapeutics Holdings CCXI ChemoCentryx MNTA Momenta Pharmaceuticals QURE Uniqure NV RGLS Regulus Therapeutics SRPT Sarepta Therapeutics VYGR Voyager Therapeutics ENGN enGene Holdings Common Stock MGX Metagenomi, Common Stock NAMS NewAmsterdam Pharma Company N.V. Ordinary Shares BL Blackline

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 10-Feb-2020

$1088

$148.32 (15.78%)

$1006

6 days ago
(02-Jul-2026)

14/16 (87.5%)

$148.32 (15.78%)

171

Buy Since 10-May-2021

$940

$52.82 (5.95%)

$940

13 days ago
(25-Jun-2026)

36/38 (94.74%)

$51.35 (5.78%)

143

Buy Since 29-Jul-2022

$1180

$292.82 (33.01%)

$1110

14 days ago
(24-Jun-2026)

32/35 (91.43%)

$327.5 (38.42%)

147

Buy Since 16-Nov-2017

$1000

$112.82 (12.72%)

$1000

27 days ago
(11-Jun-2026)

26/31 (83.87%)

$101.06 (11.24%)

122

Buy Since 17-Jul-2023

$1059

$171.82 (19.37%)

$910

1 months 23 days ago
(15-May-2026)

5/6 (83.33%)

$259.68 (32.49%)

103

Show more analysts

Please expand the browser size to see the chart

Which stock is Yanan Zhu is most bullish on?

Potential upside of $18.19 has been obtained for QURE (UNIQURE NV)

Which stock is Yanan Zhu is most reserved on?

Potential downside of -$2.56 has been obtained for NTLA (INTELLIA THERAPEUTICS)

What Year was the first public recommendation made by Yanan Zhu?

On 2017

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?